Previous 10 | Next 10 |
2024-04-01 06:08:19 ET Summary Cytokinetics' stock has seen much buyout speculation in recent months, with companies like Eli Lilly, Novartis, Johnson & Johnson, Amgen, and AstraZeneca being potential suitors. The company's Phase 3 study for aficamten, a treatment for heart di...
2024-03-27 07:03:30 ET Beyfortus (nirsevimab), a single-dose monoclonal antibody developed and commercialized in partnership by AstraZeneca ( NASDAQ: AZN ) and Sanofi ( NASDAQ: SNY ), has been approved in Japan for the prevention of lower respiratory tract disease (LRTD) cau...
2024-03-26 07:37:54 ET More on Viking Therapeutics Shaping The Future Of Obesity Treatment: GLP-1 Agonists At The Forefront Viking Therapeutics: Here To Stay In Obesity, Or A Flash In The Pan? Viking Therapeutics: VK2735 Data Supports A Buyout Jefferies start...
2024-03-25 13:47:00 ET Summary Boeing's top boss Dave Calhoun plans to step down at the end of the year. Mizuho turns cautious on the EV sector, downgrades Tesla, Rivian, and Nio. Look beyond the Magnificent 7 to the GRANOLAS in Europe - Goldman Sachs. Listen below o...
2024-03-25 13:07:32 ET Summary M&A activity in the biotech/biopharma sector is expected to remain active due to significant cash on Big Pharma's balance sheets, key patent expirations, and declining revenue from Covid related products. The oncology space continues to be a hot ...
First and only long-acting C5 complement inhibitor offers patients with AQP4 Ab+ NMOSD the potential to live relapse-free Unprecedented relapse risk reduction observed in CHAMPION-NMOSD trial underscores how ULTOMIRIS may redefine patient journey for rare neurological disease ...
2024-03-25 02:07:51 ET Summary Sanofi has underperformed the U.S. stock market lately but now offers one of the smartest growth-at-a-reasonable-price setups in Big Pharma. Sanofi is best known for its patented drug Dupixent and numerous vaccines manufactured for global use, which ...
2024-03-24 13:38:10 ET More on the GRANOLAS Sequoia Fund - SAP SE: We See A Clear Path To Enhanced Profitability ASML: Don't Be Fooled Into Buying Its Overvalued Shares Now What AstraZeneca Is Getting Through The Acquisition Of Fusion Pharmaceuticals Mo...
2024-03-21 12:56:43 ET More on AstraZeneca, Eledon Pharmaceuticals, etc. What AstraZeneca Is Getting Through The Acquisition Of Fusion Pharmaceuticals 5 Reasons AstraZeneca Stock Can Rise In 2024 AstraZeneca PLC (AZN) Q4 2023 Earnings Call Transcript Merck Ph...
2024-03-21 07:22:10 ET More on Merck Merck & Co., Inc. (MRK) Presents at Barclays 26th Annual Global Healthcare Conference (Transcript) Merck & Co., Inc. (MRK) Management presents at Leerink Partners 2024 Global Biopharma Conference (Transcript) Merck & C...
News, Short Squeeze, Breakout and More Instantly...
2024-07-02 08:30:07 ET Jefferies analyst issues HOLD recommendation for AZN on July 2, 2024 06:20AM ET. The previous analyst recommendation was Hold. AZN was trading at $77.94 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analys...
2024-06-29 22:46:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...